The positive we can look forward to in the financials is that Intangible asset impairments should nearly be finished. Mayne purchased the Teva generics portfolio in August 2016 for US $652M which is approx AU $867M on the 0.752 exchange rate at the time.
CGU (cash generating unit) impairments over the past 4 years are as follows 2018 $184M 2019 $312M 2020 $70M Dec 20 1/2 yearly $191M Total impairments of just under $758M
So only $109M of impairments to go before the entire Teva deal is written off and then it's bluesky for Mayne after that!!!
Chartsshout - just because I probably need to spell it out for you. The "blue sky for Mayne" statement is ironic.
MYX Price at posting:
30.5¢ Sentiment: Sell Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)